Navigation Links
Neurobiological Technologies Announces Suspension of Viprinex Development
Date:1/13/2009

EMERYVILLE, Calif., Jan. 13 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) (NTI(R)) today announced that, following a detailed analysis of the recent interim results of the Viprinex(TM) clinical trial, the company has decided not to develop Viprinex further for the treatment of acute ischemic stroke. Viprinex was recently studied in a clinical trial to determine whether it was effective in improving patient outcome when given within six hours of a stroke, but the trial was halted for futility following an interim analysis.

"Following a thorough review of the interim data, it was determined that there was no group of patients in which Viprinex improved outcome, and therefore further development is not warranted," said Warren W. Wasiewski, Chief Medical Officer. "We are very disappointed that another potential treatment for this devastating disease has failed to show benefit for this patient population."

The company also announced that it is reducing its workforce substantially, paring down to the minimum necessary to carry out operations and complete contractual obligations. NTI is terminating a majority of its employees this week, with additional employee terminations planned for February and March. By the end of the first quarter of calendar 2009, the reduction in workforce is expected to aggregate approximately 75% of the staff employed previously. The company is also significantly reducing other operating expenses and plans to provide further disclosure in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2008, which will be filed in February 2009.

"We are disappointed with the results of the Viprinex clinical trials. Following the receipt of these results, we have taken steps to reduce costs to preserve the company's remaining cash and to reduce
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
7. Neurobiological Technologies Sets Date for Second Quarter Financial Results
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
10. Neurobiological Technologies Sets Date for Research and Development Day
11. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider ... treatment of tinnitus. Patients listen to sound therapy that ... period of weeks to months, their tinnitus volume decreases. , ... Notched Music and Notched White Noise. Now, AudioNotch is pleased ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. – ... Warrington, Pa. , Details: The Hepatitis B Foundation, ... cure for hepatitis B and improving the quality of life ... on Friday, April 11 at Warrington Country Club in Warrington, ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up their ... of them wrote: "Take better care of my furry companion." Nowadays ... clothes and top-brand carrying cases to take the little canine or ... also feel compelled to buy some pricey toys at the pet ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a ... of peripheral vascular disease,announced today that it plans to ... 30, 2008, after the close of market on October ... teleconference at 2:00 p.m. PT,/ 5:00 p.m. ET on ...
... Cash On Hand and No Debt, NAPA, Calif., ... life sciences company engaged in the development,of technologies that ... company continues to maintain a strong, debt-free financial,position. Current ... Million,of which is invested in fully FDIC insured bank ...
... Die of Diabetes, BRUSSELS, October 13 The ... together key opinion,leaders to push for action to secure ... countries without access to care., The meeting, Access ... will be held on Saturday, October 25 in London, ...
Cached Biology Technology:VNUS Medical Technologies to Report Third-Quarter 2008 Results and Webcast Teleconference on October 29 2Senetek Affirms Strong Financial Position 2Senetek Affirms Strong Financial Position 3International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 2International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive 3
(Date:4/23/2014)... of dementia and affects some 400,000 people in Spain ... One of the reasons for this is the lack ... in nerve transmissions and the loss of memory in ... Institute of Neuroscience at the Universitat Autnoma de Barcelona ... and were able to develop a gene therapy which ...
(Date:4/23/2014)... is leading a 2 million Food Standards Agency (FSA) ... premises and industry workers. , Norovirus outbreaks can ... a batch of frozen strawberries infected 11,000 people in ... understanding of which strains cause infection and which foods ... , Researchers will produce data that will help ...
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2New research focuses on streamwater chemistry, landscape variation 2
... , LAKE MARY, Fla. , April 26 Roundtable Concepts ... are of the highest quality components and specifications. A great review has been ... limited time only, is offering this promotional special: the RTC View 32" LCD ... at www.rtcview.com . , , ...
... 26 Kevin Harvick and the Shell-Pennzoil ... in a NASCAR Sprint Cup Series points-scoring race.  The Shell-Pennzoil ... Aaron,s 499 at Talladega Superspeedway where Harvick made a last-lap ... just 0.011 seconds to spare.  The finish was the eighth ...
... , April 26 Desarrolladora Homex,S.A.B. de C.V. ("Homex" or ... Quarter ended on March 31, 2010 (1). , ... As previously stated, effective ... Homex recognizes its revenues, costs and expenses when the,Company has transferred the ...
Cached Biology News:Roundtable Concepts Inc., the Company that has Officially Licensed Marvel Comic TVs and Officially Licensed Collegiate TVs, has just Launched their Own Line of HDTVs Named RTC View 2Harvick Breaks 115-Race Winless Streak To Take the Checkered Flag in Dramatic Finish at Talladega 2Harvick Breaks 115-Race Winless Streak To Take the Checkered Flag in Dramatic Finish at Talladega 3Harvick Breaks 115-Race Winless Streak To Take the Checkered Flag in Dramatic Finish at Talladega 4Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 2Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 3Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 4Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 5Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 6Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 7Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent 8
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: